Health Trials

Malignant Peritoneal Mesothelioma, Advanced

2

Review clinical trials related to Malignant Peritoneal Mesothelioma, Advanced. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

CT-95 in Advanced Cancers Associated With Mesothelin Expression

This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.

Participants needed: 70
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Context Therapeutics Inc.Updated: Jun 12, 2026Locations: 9
Eligibility criteria

ECOG 0 or 1 [+3]

Uncontrolled significant active infection or any medical or other condition that... [+3]

Read more
Status: Recruiting

Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM

To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.

Participants needed: 28
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: Aug 7, 2024Locations: 1
Eligibility criteria

Fully understand the study and voluntarily sign the informed consent form; [+7]

Unable to adhere to the study protocol or procedures; [+17]

Read more